Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells $122,537.94 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Matthew Link sold 20,734 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $5.91, for a total transaction of $122,537.94. Following the completion of the sale, the insider now directly owns 726,838 shares of the company’s stock, valued at approximately $4,295,612.58. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Sight Sciences Trading Up 0.3 %

NASDAQ SGHT opened at $5.97 on Monday. Sight Sciences, Inc. has a 12 month low of $1.04 and a 12 month high of $8.45. The stock has a 50-day simple moving average of $6.31 and a 200 day simple moving average of $6.30. The company has a current ratio of 11.01, a quick ratio of 10.50 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $297.04 million, a PE ratio of -5.33 and a beta of 2.71.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06. The business had revenue of $21.37 million during the quarter, compared to analyst estimates of $21.32 million. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.90%. During the same period in the previous year, the firm earned ($0.30) EPS. Research analysts forecast that Sight Sciences, Inc. will post -1 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Steele Capital Management Inc. bought a new position in shares of Sight Sciences in the 2nd quarter valued at about $67,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Sight Sciences during the 1st quarter worth about $59,000. SG Americas Securities LLC bought a new stake in Sight Sciences in the 3rd quarter valued at $75,000. The Manufacturers Life Insurance Company bought a new position in Sight Sciences in the 2nd quarter valued at approximately $95,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Sight Sciences by 51.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock valued at $141,000 after buying an additional 9,106 shares in the last quarter. 55.51% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

SGHT has been the topic of a number of recent research reports. Lake Street Capital initiated coverage on Sight Sciences in a research report on Wednesday, August 21st. They issued a “buy” rating and a $10.00 price objective on the stock. Morgan Stanley raised their price target on Sight Sciences from $5.40 to $6.50 and gave the company an “equal weight” rating in a report on Monday, July 15th. Citigroup boosted their price objective on Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a report on Wednesday, July 10th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research note on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Sight Sciences presently has a consensus rating of “Hold” and a consensus price target of $7.25.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.